CA2869729C - Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway - Google Patents

Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway Download PDF

Info

Publication number
CA2869729C
CA2869729C CA2869729A CA2869729A CA2869729C CA 2869729 C CA2869729 C CA 2869729C CA 2869729 A CA2869729 A CA 2869729A CA 2869729 A CA2869729 A CA 2869729A CA 2869729 C CA2869729 C CA 2869729C
Authority
CA
Canada
Prior art keywords
utr
homopolymer
regions
nucleotides
chr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2869729A
Other languages
English (en)
French (fr)
Other versions
CA2869729A1 (en
Inventor
Diether Lambrechts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Life Sciences Research Partners vzw
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Life Sciences Research Partners vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB, Life Sciences Research Partners vzw filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of CA2869729A1 publication Critical patent/CA2869729A1/en
Application granted granted Critical
Publication of CA2869729C publication Critical patent/CA2869729C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2869729A 2012-04-10 2013-04-10 Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway Active CA2869729C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261622383P 2012-04-10 2012-04-10
US61/622,383 2012-04-10
US201261638955P 2012-04-26 2012-04-26
US61/638,955 2012-04-26
EP13161395.2 2013-03-27
EP13161395 2013-03-27
PCT/EP2013/057516 WO2013153130A1 (en) 2012-04-10 2013-04-10 Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway

Publications (2)

Publication Number Publication Date
CA2869729A1 CA2869729A1 (en) 2013-10-17
CA2869729C true CA2869729C (en) 2021-12-28

Family

ID=47915624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869729A Active CA2869729C (en) 2012-04-10 2013-04-10 Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway

Country Status (10)

Country Link
EP (2) EP2836606B1 (zh)
JP (1) JP6578205B2 (zh)
KR (1) KR20150005597A (zh)
CN (2) CN114058704A (zh)
AU (1) AU2013246909B2 (zh)
BR (1) BR112014025185B1 (zh)
CA (1) CA2869729C (zh)
ES (1) ES2906023T3 (zh)
RU (1) RU2014145017A (zh)
WO (1) WO2013153130A1 (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294529B2 (en) 2012-04-10 2019-05-21 Life Sciences Research Partners Vzw Microsatellite instability markers in detection of cancer
US10633707B2 (en) 2012-04-10 2020-04-28 Vib Vzw Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway
CN107208152B (zh) * 2015-03-06 2021-03-23 深圳华大基因股份有限公司 检测突变簇的方法和装置
EP3353320B1 (en) 2015-09-22 2023-06-07 Biocartis NV Improved detection of short homopolymeric repeats
WO2017112738A1 (en) * 2015-12-22 2017-06-29 Myriad Genetics, Inc. Methods for measuring microsatellite instability
AU2017281099A1 (en) * 2016-06-21 2019-01-03 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
GB201614474D0 (en) * 2016-08-24 2016-10-05 Univ Of Newcastle Upon Tyne The Methods of identifying microsatellite instability
GB201621969D0 (en) * 2016-12-22 2017-02-08 Genome Res Ltd Hotspots for chromosomal rearrangement in breast and ovarian cancers
CN106755501B (zh) * 2017-01-25 2020-11-17 广州燃石医学检验所有限公司 一种基于二代测序的同时检测微卫星位点稳定性和基因组变化的方法
US11447830B2 (en) 2017-03-03 2022-09-20 Board Of Regents, The University Of Texas System Gene signatures to predict drug response in cancer
JP2020530763A (ja) * 2017-07-12 2020-10-29 アンスティテュート キュリー マイクロサテライト配列中の突然変異を検出する方法
CN107267505B (zh) * 2017-07-21 2020-10-30 首都医科大学 微卫星标记及其在结直肠癌的预后判定和/或化疗敏感性预测中的应用
EP3645723A1 (en) * 2017-10-16 2020-05-06 H. Hoffnabb-La Roche Ag NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
JP6955035B2 (ja) * 2017-11-16 2021-10-27 イルミナ インコーポレイテッド マイクロサテライト不安定性を決定するためのシステム及び方法
EP3514247B1 (en) 2018-01-23 2020-03-11 Biocartis NV Biomarker panel and methods for detecting microsatellite instability in cancers
WO2019145306A1 (en) 2018-01-23 2019-08-01 Biocartis Nv Biomarker panel and methods for detecting microsatellite instability in cancers
US20210005286A1 (en) 2018-01-23 2021-01-07 Biocartis Nv Methods for the analysis of dissociation melt curve data
US20210047696A1 (en) * 2018-03-28 2021-02-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
CN108753834B (zh) * 2018-05-28 2021-11-23 上海海洋大学 ddx27基因缺失斑马鱼突变体的制备方法
WO2019236448A1 (en) * 2018-06-04 2019-12-12 The Broad Institute, Inc. Therapeutic treatment of microsatellite unstable cancers
EP3806850A2 (en) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
CN108866190B (zh) * 2018-07-12 2022-01-28 吉林大学 一种卵巢恶性肿瘤易感性预测试剂盒及系统
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
CN108676889B (zh) * 2018-07-12 2022-02-01 吉林大学 一种胃腺癌易感性预测试剂盒及系统
CN108841960B (zh) * 2018-07-12 2022-02-01 吉林大学 一种结肠腺癌易感性预测试剂盒及系统
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
CN112930569A (zh) * 2018-08-31 2021-06-08 夸登特健康公司 无细胞dna中的微卫星不稳定性检测
SG11202102528UA (en) * 2018-09-14 2021-04-29 Lexent Bio Inc Methods and systems for assessing microsatellite instability
US20200118644A1 (en) * 2018-10-15 2020-04-16 Tempus Labs, Inc. Microsatellite instability determination system and related methods
WO2020165361A1 (en) 2019-02-14 2020-08-20 Vib Vzw Retrotransposon biomarkers
CN110184358A (zh) * 2019-06-25 2019-08-30 台州市立医院 甲状腺癌早期诊断用的oit3基因及其应用
EP3863019A1 (en) 2020-02-07 2021-08-11 Sophia Genetics S.A. Methods for detecting and characterizing microsatellite instability with high throughput sequencing
CN114182011B (zh) * 2020-09-14 2023-09-15 中山大学附属第六医院 检测微卫星bat25位点稳定性的引物对、试剂盒及方法
CN112522405B (zh) * 2020-12-10 2023-03-21 首都医科大学 Magi3在预测结直肠癌患者预后或化疗敏感性中的应用
CN112626216B (zh) * 2020-12-31 2022-11-01 复旦大学附属中山医院 一种检测肿瘤微卫星不稳定性状态的组合物及其应用
CN112708679B (zh) * 2021-01-27 2023-01-24 厦门艾德生物医药科技股份有限公司 检测人群微卫星不稳定性的生物标志物组及其应用
CA3226694A1 (en) 2021-07-15 2023-01-19 Katholieke Universiteit Leuven Biomarkers predicting response of breast cancer to immunotherapy
CN113736790B (zh) * 2021-10-14 2023-05-02 四川农业大学 一种敲除鸭hnRNPA3基因的sgRNA、细胞系及其构建方法和应用
CN114854861A (zh) * 2022-05-20 2022-08-05 北京大学第一医院 基因组合制备人肿瘤同源重组缺陷、肿瘤突变负荷和微卫星不稳定性分级检测产品的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60113945T2 (de) * 2000-11-15 2006-06-29 Roche Diagnostics Gmbh Verfahren zur Analyse von Wiederkehrenden PCR-Podukten, das auf der Analyse von DNS-Schmelzkurven basiert
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
CN102230004B (zh) * 2011-06-08 2012-12-26 北京阅微基因技术有限公司 肿瘤细胞微卫星不稳定状态的复合扩增体系及检测试剂盒

Also Published As

Publication number Publication date
EP3998347A1 (en) 2022-05-18
JP6578205B2 (ja) 2019-09-18
CA2869729A1 (en) 2013-10-17
JP2015516144A (ja) 2015-06-08
BR112014025185B1 (pt) 2022-06-28
AU2013246909B2 (en) 2018-10-11
RU2014145017A (ru) 2016-05-27
CN104379765A (zh) 2015-02-25
BR112014025185A2 (pt) 2021-06-01
CN114058704A (zh) 2022-02-18
ES2906023T3 (es) 2022-04-12
WO2013153130A1 (en) 2013-10-17
EP2836606A1 (en) 2015-02-18
AU2013246909A1 (en) 2014-10-30
KR20150005597A (ko) 2015-01-14
EP2836606B1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
CA2869729C (en) Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway
US10633707B2 (en) Markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the DNA base excision repair pathway
US20220010385A1 (en) Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
AU2020223754B2 (en) Methods and materials for assessing loss of heterozygosity
US10294529B2 (en) Microsatellite instability markers in detection of cancer
Agathangelidis et al. Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
EP3327148A1 (en) Methods of predicting the status of brca1 and brca2 genes in a cancer cell
EP2885427B1 (en) Colorectal cancer methylation marker
CN117597456A (zh) 用于确定肿瘤生长的速度的方法
US20220025466A1 (en) Differential methylation
Nassar et al. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma
Kovalchuk Cancer and genomic instability
Díaz Navarro Development of a tool for the identification of somatic mutations and analysis of non-coding mutations in cancer
Egolf Defining the Landscape of Rare Inherited and de novo Germline Structural Variation in Neuroblastoma
Brzezinski Integrated Genetic and Epigenetic Profiling of Wilms Tumors and Beckwith Wiedemann Syndrome
Stuckel Global DNA Methylation Analysis in Relapsed Pre-B Cell Acute Lymphoblastic Leukemia
Alsolami Characterisation of the mutational landscape of chronic lymphocytic leukaemia using genome-wide approaches

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171114